In the COMFORT studies, the number of patients with grade 3 or 4 anemia was higher for ruxolitinib compared with placebo; however, the lowest Hb levels were observed at weeks 8 to 12 of treatment and recovered to near-baseline levels by week 24 [14, 18, 19]. The gene discussed is GSTM1; the disease is anemia.